Stock Analysis
InnoCan Pharma First Quarter 2024 Earnings: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)
InnoCan Pharma (CSE:INNO) First Quarter 2024 Results
Key Financial Results
- Revenue: US$6.77m (up 334% from 1Q 2023).
- Net loss: US$1.77m (loss widened by 39% from 1Q 2023).
- US$0.007 loss per share (further deteriorated from US$0.005 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
InnoCan Pharma shares are down 3.3% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 2 warning signs for InnoCan Pharma you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:INNO
InnoCan Pharma
A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.